| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||
| Acetyl-L-carnitine (ALC, ALCAR) — an endogenous acetylated derivative of L-carnitine that participates in the carnitine/acylcarnitine system for shuttling acyl groups between cellular compartments and buffering mitochondrial acetyl-CoA/CoA balance. A naturally occurring molecule involved in mitochondrial energy metabolism. It is a small-molecule nutrient/“mitochondrial co-factor” used clinically or as a supplement in various jurisdictions, with mechanistic relevance to fatty-acid oxidation flux control and (context-dependent) support of cytosolic acetyl-CoA pools that feed lipid synthesis and protein acetylation. In oncology contexts, its relevance is primarily metabolic (substrate handling and acetyl unit trafficking) plus supportive-care use cases rather than a validated anticancer drug modality. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral dosing produces measurable systemic exposure with reported Tmax on the order of hours and plasma half-life on the order of hours in small human PK studies; tissue distribution depends on carnitine transporters (e.g., OCTN2) including across the blood–brain barrier. Systemic levels achievable with typical supplementation are generally far below the high millimolar exposures sometimes used in in-vitro cancer studies, so concentration-driven cytotoxic claims often have limited translational relevance unless a mechanism is triggered at low exposure or via compartmental flux effects. In-vitro vs systemic exposure relevance: Many reported “direct anticancer” effects occur at supraphysiologic concentrations and may not map to achievable plasma/tissue levels; flux-level effects on acetyl-group trafficking and FAO may be more relevant at physiologic ranges but are strongly context-dependent (tumor type, ACLY/ACSS2 status, nutrient environment). Clinical evidence status: Supportive-care evidence is mixed and indication-specific; a large randomized trial found no benefit for taxane-related chemotherapy-induced peripheral neuropathy at 12 weeks and worsening at longer follow-up, arguing against routine use for CIPN prevention. Evidence for cancer-related fatigue/cachexia has been explored (often as L-carnitine class rather than ALCAR specifically) with meta-analytic conclusions generally not supporting efficacy in lower-bias trials. -ALC supports mitochondrial energy metabolism by transporting fatty acids into mitochondria.-Antioxidant effects: Reduces oxidative stress and lipid peroxidation. -In cancer patients with fatigue or cachexia (wasting), ALC can improve energy metabolism and physical function. -Acetyl-L-carnitine (ALC or ALCAR) levels are often reduced in Alzheimer's disease (AD) — especially in the brain and cerebrospinal fluid (CSF). -ALC is present at high concentrations in the brain -Carnitine is important in the β-oxidation of fatty acids and the acetyl portion can be used to maintain acetyl-CoA levels -ALC is active in cholinergic neurons, where it is involved in the production of acetylcholine -ALC significantly reduces Aβ-induced cytotoxicity, protein oxidation and lipid peroxidation in a concentration-dependent manner. -ALC can cause an increase in the level of ADAM10 Acetyl-L-carnitine: mechanistic pathway ranking in cancer contexts
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: |
| Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress. Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system. cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment. While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied. Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy. Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death. Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion. Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS). "...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..." "Cancer cells have a high level of GSH compared to normal cells." "...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy." The loss of GSH is broadly known to be directly related to the apoptosis progression. |
| 5319- | ALC, | l-carnitine and cancer cachexia: Clinical and experimental aspects |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:350 Target#:137 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid